Surrozen (NASDAQ:SRZN) Director Buys $236,551.77 in Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 11,893 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were purchased at an average cost of $19.89 per share, with a total value of $236,551.77. Following the purchase, the director directly owned 1,005,732 shares in the company, valued at approximately $20,004,009.48. The trade was a 1.20% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 20th, Tim Kutzkey acquired 18,052 shares of Surrozen stock. The stock was acquired at an average cost of $19.60 per share, for a total transaction of $353,819.20.
• On Friday, January 16th, Tim Kutzkey bought 2,562 shares of Surrozen stock. The shares were acquired at an average price of $20.00 per share, with a total value of $51,240.00.
• On Wednesday, January 14th, Tim Kutzkey purchased 5,523 shares of Surrozen stock. The stock was acquired at an average cost of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey purchased 12,470 shares of Surrozen stock. The stock was acquired at an average price of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey acquired 15,100 shares of Surrozen stock. The shares were acquired at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The shares were bought at an average price of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The stock was bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The shares were bought at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Stock Performance

Surrozen stock opened at $20.00 on Friday. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $24.94. The company has a market capitalization of $171.40 million, a price-to-earnings ratio of -0.90 and a beta of 0.58. The stock has a fifty day moving average of $19.26 and a two-hundred day moving average of $14.21.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. On average, analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SRZN. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Institutional Investors Weigh In On Surrozen

Several hedge funds have recently modified their holdings of SRZN. Stempoint Capital LP increased its position in Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after purchasing an additional 445,713 shares during the last quarter. Braidwell LP acquired a new position in shares of Surrozen in the 2nd quarter valued at $1,252,000. Millennium Management LLC acquired a new position in shares of Surrozen in the 3rd quarter valued at $1,414,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Surrozen during the 3rd quarter worth $889,000. Finally, Armistice Capital LLC acquired a new stake in shares of Surrozen during the 2nd quarter worth $536,000. 66.57% of the stock is owned by institutional investors and hedge funds.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.